MAPT and Alzheimer disease: In the same study, as a discriminatory diagnostic biomarker, plasma p-tau217 also outperformed plasma p-tau181 for AD versus other neurodegenerative disorders, with an accuracy on par with CSF p-tau217, CSF p-tau181, and tau PET.